Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a much-needed boost in a key market where demand has been falling among women.

The China National Medical Products Administration (NMPA) has granted expanded approval to MSD's GARDASIL, [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for use in males aged nine to 26 years.

The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV vaccine, after US pharmaceutical giant Merck announced its quadrivalent HPV vaccine Gardasil had been approved for additional indications by the National Medical Products Administration.

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration, providing a much-needed boost to the company in a key market.

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the US drug giant after a rush among women to get the shot lost steam.

The HPV vaccine, Gardasil, has gained approval for additional indications from China's National Medical Products Administration, becoming the first and only HPV vaccine authorized for use in men in China,